Related Experiment Videos
[Prostaglandins in newborn infants with severe cardiopathy]
Insights
Prostaglandin E1 infusion improved oxygen levels and hemodynamics in newborns with severe congenital heart disease, facilitating timely corrective surgery. This therapy is a valuable tool for managing critical cardiac conditions in infants.
Area of Science:
- Pediatric Cardiology
- Neonatology
- Pharmacology
Background:
- Severe congenital heart disease (CHD) poses significant challenges in neonates.
- Maintaining hemodynamic stability is crucial for infants with critical CHD.
- Prostaglandin E1 (PGE1) is a vasodilator with potential therapeutic applications in neonates.
Purpose of the Study:
- To evaluate the efficacy of prostaglandin E1 infusion in improving hemodynamic parameters in newborns with severe CHD.
- To assess the impact of PGE1 on oxygenation and peripheral circulation.
- To determine the safety and survival rates associated with PGE1 therapy and subsequent surgery.
Main Methods:
- A study involving 26 newborn infants with severe CHD receiving PGE1 infusion.
- Patients were categorized into three groups based on pulmonary and systemic blood flow.
- PGE1 was administered at an initial dose of 0.05 mcg/kg/minute.
Main Results:
- Significant improvements in blood oxygenation (PO2) were observed in 10/12 patients in Group I and 9/10 in Group II.
- Enhanced peripheral pulses and increased blood pressures were noted in Group II.
- Hyperthermia was the most frequent complication, managed by dose reduction; 52.6% overall survival post-surgery.
Conclusions:
- Prostaglandin E1 infusion is effective in stabilizing hemodynamic conditions in neonates with severe CHD.
- PGE1 therapy facilitates the timing of corrective surgical interventions within the first month of life.
- PGE1 is a valuable therapeutic option for improving outcomes in critically ill infants with congenital heart defects.
Abstract:
Between February 1983 and December 1985 authors have studied 26 newborn infants with severe congenital heart disease who received prostaglandin E1 infusion as therapy. Onset of therapy was before 5 days of age in 15 patients, between 5 and 7 days of age in 7 cases and after 14 days of age in the remaining ones. Initial dose was 0.05 mcg/kg/minutes and mean duration of infusion was 131.9 +/- 19.0 hours. Patients were divided into 3 groups according to pulmonary and systemic blood flows: Group I, with cyanosis and diminished pulmonary blood flow (12 cases); Group II, with diminished systemic blood flow (10 cases); and group III, with cyanosis and normal or increased pulmonary blood flow (4 cases). Most patients of groups I (10/12) and II (9/10) improved levels of blood PO2: mean increments of 17.8 +/- 7.4 and 17.5 +/- 13.3 torr respectively. Peripheral pulses also improved in four extremities in patients from group II; systolic and diastolic pressures increased 16 +/- 9.6 and 5 +/- 2.2 mmHg, respectively. No improvement was observed in patients from group III, with exception of patients with transposition of great vessels. Most frequent complication of prostaglandin infusion was hyperthermia, which was observed in 16 cases but disappeared in all with moderate reduction of doses. Appropriate surgery was performed in 19 patients, with an overall survival of 52.6%. In conclusion, prostaglandin infusion appears to be a very valued tool to improve the hemodynamic condition in newborn infants with severe congenital heart disease and thus allow the practice of corrective surgery during first month of life.